Two days of fruitful debate in the 5th CIMAvax-EGF International Workshop on the first registered therapeutic vaccine against lung cancer, confirmed that after two decades of clinical experience in the use of this vaccine, the treatment has been proven safe and effective given the positive reaction of patients, the increase in survival rates and improved quality of life.
An excellent prognosis
An excellent prognosis in a context where lung cancer, according to the Annual Health Statistics report 2014, is among the top causes of death for both men and women in the country, and is one of the illnesses showing the greatest increase in both genders.
The ideal place to present the final results of the study
The Workshop, organized by CIMAB S.A – biopharmaceutical entity dedicated to the development and commercialization of cancer medicines, affiliated with the Molecular Immunology Center (CIM) – was the ideal place to present the…
View original post 501 more words